NEW YORK (GenomeWeb) – Myriad Genetics said today that it will submit its BRACAnalysis CDx to Japan's Pharmaceuticals and Medical Devices Agency for regulatory approval, alongside AstraZeneca's PARP inhibitor Lynparza (olaparib).
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.